Timeline

Nathalie Jolly

Head of Facility

15 Mar 2023

project

CoVariant – Comprendre les déterminants de l’immunité muqueuse et optimiser le diagnostic de l’infection aux variants du SARS-CoV-2

15 Mar 2023

project

Études nécessitant l’accès aux données du Système National des Données de Santé (SNDS).

04 Jan 2023

news

PREGASIGN: Signatures de biomarqueurs circulants pour la détection des lésions de prénéoplasie et de cancer gastrique

01 Sep 2022

publication

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.

07 Feb 2022

project

Ressources for good practices in implementing clinical research and translational research on human samples and data

01 Jan 2022

publication

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

16 Jul 2021

news

Séro-épidémiologie du SARS-CoV-2 (études CORSER)

01 Apr 2021

publication

SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

06 Nov 2020

news

Suivi de la persistance de la réponse immunitaire contre le SARS-CoV-2 au sein de la cohorte de Crépy-en-Valois (COVID-Oise)

02 Sep 2020

publication

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

01 Sep 2020

publication

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.

26 Jun 2020

news

Curie-O-SA : étude de la réponse immunitaire contre le virus SARS-CoV2

25 Jun 2018

project

Institut Pasteur’s commitments for clinical trials

21 Jul 2015

team

Clinical Research Coordination Office

09 Jan 2009

publication

Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial

03 Dec 2007

publication

Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers

01 Aug 2003

publication

Increased production of interferon-gamma by Leishmania homologue of the mammalian receptor for activated C kinase-reactive CD4+ T cells among human blood mononuclear cells: an early marker of exposure to Leishmania?

A little guide for advanced search:

CoVariant – Comprendre les déterminants de l’immunité muqueuse et optimiser le diagnostic de l’infection aux variants du SARS-CoV-2

Études nécessitant l’accès aux données du Système National des Données de Santé (SNDS).

PREGASIGN: Signatures de biomarqueurs circulants pour la détection des lésions de prénéoplasie et de cancer gastrique

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.

Ressources for good practices in implementing clinical research and translational research on human samples and data

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Séro-épidémiologie du SARS-CoV-2 (études CORSER)

SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

Suivi de la persistance de la réponse immunitaire contre le SARS-CoV-2 au sein de la cohorte de Crépy-en-Valois (COVID-Oise)

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.

Curie-O-SA : étude de la réponse immunitaire contre le virus SARS-CoV2

Institut Pasteur’s commitments for clinical trials

Clinical Research Coordination Office

Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial

Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers

Increased production of interferon-gamma by Leishmania homologue of the mammalian receptor for activated C kinase-reactive CD4+ T cells among human blood mononuclear cells: an early marker of exposure to Leishmania?